GlassScriptPhysician profile
Kenya M Kidd
NPI 1881601045
$6,595.91
in general payments reported to CMS, 2019-2025
55 companies · $2,042 in 2025
The $2,042 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $878 · 2023: $1,237 · 2024: $2,026 · 2025: $2,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,027 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,026.77 |
| Education | $278.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $711.30 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $677.17 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $471.90 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $444.43 | 2022-2025 | |
| Celgene Corporation | $438.47 | 2022-2025 | Reblozyl, Pomalyst, Pomalyst |
| Incyte Corporation | $343.45 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Eisai INC. | $285.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $274.20 | 2021-2025 | Imfinzi, Calquence, Enhertu |
| Lilly USA, LLC | $210.33 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $201.56 | 2023-2025 | |
| Exelixis INC. | $194.23 | 2021-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $186.67 | 2023-2025 | Libtayo |
| Amgen INC. | $184.50 | 2021-2022 | |
| Pfizer INC. | $144.66 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $132.27 | 2023-2025 | Monoferric |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenya Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.